Data indicated a trend toward reduced incidence of vaso-occlusive crises over 52 weeks and increased hemoglobin response at 24 weeks compared with placeboResults to be confirmed in the phase 3 component of the HIBISCUS trial

The Chandler Arizonan

Chandler

Maricopa County

Arizona

United States

Phase 2 data from the ongoing HIBISCUS study shows promise that investigational etavopivat could reduce the incidence of vaso-occlusive crises in people with sickle cell disease

Media Bias/Fact Check

Queen Creek Tribune

Queen Creek

Gilbert Sun News

Beam's novel conditioning platform shows remarkable 80% efficacy in primate studies for sickle cell disease, demonstrating successful long-term cell engraftment without toxicity.

stocktitan.net

Beam Therapeutics Achieves Breakthrough in Sickle Cell Treatment with Promising ESCAPE Platform Data

Etavopivat, an oral activator of red blood cell pyruvate kinase, showed promise in reducing vaso-occlusive crises and improving hemoglobin levels in patients with sickle cell disease. Results from the HIBISCUS trial revealed a decrease in annualized vaso-occlusive crisis rates, an increase in hemoglobin levels, reduced fatigue, and improved hemolysis markers with etavopivat compared to placebo. The drug may serve as a second-line therapy to hydr…

Dataemia

Etavopivat could offer ‘great benefit’ in sickle cell disease

The therapy uses a novel pyruvate kinase activator mechanism and warrants further investigation in an ongoing phase 3 trial.

hcplive.com

Etavopivat Well-Tolerated With Some Disease-Modifying Activity in SCD

Novo Nordisk

Phase 2 data from the ongoing HIBISCUS study shows promise that investigational etavopivat could reduce the incidence of vaso-occlusive crises in people with sickle cell disease

Coverage Details

Give the gift of Perspective

Bias Distribution

Ownership

Similar News Topics

Similar News Topics